BR112013003530A2 - ''produto farmacêutico, kit, uso e preparações'' - Google Patents

''produto farmacêutico, kit, uso e preparações''

Info

Publication number
BR112013003530A2
BR112013003530A2 BR112013003530A BR112013003530A BR112013003530A2 BR 112013003530 A2 BR112013003530 A2 BR 112013003530A2 BR 112013003530 A BR112013003530 A BR 112013003530A BR 112013003530 A BR112013003530 A BR 112013003530A BR 112013003530 A2 BR112013003530 A2 BR 112013003530A2
Authority
BR
Brazil
Prior art keywords
preparations
kit
pharmaceutical
Prior art date
Application number
BR112013003530A
Other languages
English (en)
Inventor
Brian Higgins
Brian Lestini
Fei Su
Kapil Dhingra
Kathryn E Packman
Kenneth Kolinsky
Richard J Lee
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013003530(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013003530A2 publication Critical patent/BR112013003530A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112013003530A 2010-08-17 2011-08-16 ''produto farmacêutico, kit, uso e preparações'' BR112013003530A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37429610P 2010-08-17 2010-08-17
PCT/EP2011/064050 WO2012022724A1 (en) 2010-08-17 2011-08-16 Combination anti - cancer therapy

Publications (1)

Publication Number Publication Date
BR112013003530A2 true BR112013003530A2 (pt) 2016-06-28

Family

ID=44532840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003530A BR112013003530A2 (pt) 2010-08-17 2011-08-16 ''produto farmacêutico, kit, uso e preparações''

Country Status (26)

Country Link
US (1) US8709419B2 (pt)
EP (1) EP2605764B1 (pt)
JP (1) JP5758003B2 (pt)
KR (1) KR101475167B1 (pt)
CN (1) CN103153292B (pt)
AR (1) AR082691A1 (pt)
AU (1) AU2011290818B2 (pt)
BR (1) BR112013003530A2 (pt)
CA (1) CA2807222A1 (pt)
DK (1) DK2605764T3 (pt)
ES (1) ES2535000T3 (pt)
HR (1) HRP20150648T1 (pt)
HU (1) HUE025187T2 (pt)
IL (1) IL224395A (pt)
MX (1) MX349878B (pt)
MY (1) MY161288A (pt)
NZ (1) NZ606251A (pt)
PL (1) PL2605764T3 (pt)
PT (1) PT2605764E (pt)
RS (1) RS53959B1 (pt)
RU (1) RU2607596C2 (pt)
SG (1) SG188207A1 (pt)
SI (1) SI2605764T1 (pt)
TW (1) TWI530287B (pt)
WO (1) WO2012022724A1 (pt)
ZA (1) ZA201300967B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
NZ744862A (en) 2012-08-17 2019-06-28 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafenib
WO2015112888A1 (en) 2014-01-24 2015-07-30 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
US20170027940A1 (en) * 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
PL3215158T3 (pl) * 2014-11-07 2019-11-29 Ai Therapeutics Inc Apilimod do zastosowania do leczenia raka nerki
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
WO2019195959A1 (en) * 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516807A (en) * 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
PT1251850E (pt) 2000-01-26 2006-10-31 Schering Corp Utilizacao de uma preparacao de combinacao na terapia do cancro
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AU2001261473B2 (en) 2000-05-15 2006-09-14 Board Of Trustees Of The University Of Arkansas Compositions and methods for the treatment of colorectal cancer
US6458816B1 (en) 2000-10-13 2002-10-01 Vion Pharmaceuticals, Inc. Modified prodrug forms of AP/AMP
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080193445A1 (en) 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
EP1492568A1 (en) * 2002-04-08 2005-01-05 SmithKline Beecham Corporation Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
WO2005062795A2 (en) 2003-12-19 2005-07-14 Plexxikon, Inc. Compounds and methods for development of ret modulators
US20070281041A1 (en) 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
CA2566971A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (cpt-11) and an egfr-inhibitor
KR100851271B1 (ko) * 2004-06-03 2008-08-08 에프. 호프만-라 로슈 아게 이리노테칸 （ｃｐｔ-１１） 및 ｅｇｆｒ-억제제를 이용한치료
US20090269344A1 (en) 2005-04-14 2009-10-29 Salvatore Siena Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
US20090214562A1 (en) 2005-05-03 2009-08-27 Karel Steven J Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20060257400A1 (en) 2005-05-13 2006-11-16 Bristol-Myers Squibb Company Combination therapy
EP1893612B1 (en) 2005-06-22 2011-08-03 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
WO2007063013A1 (en) 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
CA2650953A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
CA2662508A1 (en) 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
JPWO2008111441A1 (ja) 2007-03-05 2010-06-24 協和発酵キリン株式会社 医薬組成物
RU2468819C2 (ru) 2007-08-01 2012-12-10 Идера Фармасьютикалз, Инк. Новые синтетические агонисты tlr9
CN102014624A (zh) * 2008-02-08 2011-04-13 帕纳德制药公司 治疗肺癌的吡铂和氨柔比星
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
EP2419727A1 (en) 2009-04-14 2012-02-22 Schering Corporation Interferon-alfa sensitivity biomarkers
MX2011012311A (es) 2009-05-21 2011-12-14 Schering Corp Marcadores geneticos asociados con la respuesta al interferon alfa.
MX338856B (es) 2009-08-24 2016-05-03 Genentech Inc Determinacion de sensibilidad de celulas al tratamiento del inhibidor de b-raf mediante la deteccion de mutacion de kras y niveles de expreson de rtk.
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Also Published As

Publication number Publication date
US20120045434A1 (en) 2012-02-23
KR20130043225A (ko) 2013-04-29
ZA201300967B (en) 2015-11-25
EP2605764A1 (en) 2013-06-26
HRP20150648T1 (hr) 2015-07-31
CA2807222A1 (en) 2012-02-23
RS53959B1 (en) 2015-08-31
HUE025187T2 (en) 2016-07-28
PL2605764T3 (pl) 2015-08-31
MX349878B (es) 2017-08-16
TWI530287B (zh) 2016-04-21
CN103153292A (zh) 2013-06-12
KR101475167B1 (ko) 2014-12-19
RU2607596C2 (ru) 2017-01-10
IL224395A (en) 2017-09-28
AU2011290818A1 (en) 2013-02-07
NZ606251A (en) 2015-02-27
RU2013110124A (ru) 2014-09-27
CN103153292B (zh) 2016-06-29
AU2011290818B2 (en) 2015-08-27
WO2012022724A1 (en) 2012-02-23
ES2535000T3 (es) 2015-05-04
TW201212915A (en) 2012-04-01
MX2013001518A (es) 2013-02-27
JP5758003B2 (ja) 2015-08-05
DK2605764T3 (en) 2015-04-07
SI2605764T1 (sl) 2015-06-30
US8709419B2 (en) 2014-04-29
MY161288A (en) 2017-04-14
SG188207A1 (en) 2013-04-30
EP2605764B1 (en) 2015-03-18
PT2605764E (pt) 2015-06-02
AR082691A1 (es) 2012-12-26
JP2013537544A (ja) 2013-10-03

Similar Documents

Publication Publication Date Title
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
BR112012013148A2 (pt) formulação farmacêutica e uso
BR112013023174A2 (pt) "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos"
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BR112012002349A2 (pt) composto,e, uso do mesmo
BR112012003792A2 (pt) gel tópico, e, uso do gel tópico.
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112013010988A2 (pt) composição fluída e uso
BRPI1014914A2 (pt) Composição contendo trehalulose, sua preparação e uso
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0914152A2 (pt) preparações de xampu
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
IT1398268B1 (it) Glicerosomi e loro impiego in preparazioni farmaceutiche e cosmetiche per uso topico
BR112012003715A8 (pt) misturas de corantes dispersos, sua preparação e uso
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]